Assertio Holdings to Be Acquired by Garda for $18.00

Garda Therapeutics has entered into an agreement to acquire Assertio Holdings through a cash tender offer followed by a merger. The offer provides for $18.00 per share in cash as the base purchase price.

The tender offer price also includes one contingent value right per share under a CVR agreement, with potential additional cash payments tied to the CVR terms. After the offer, the purchaser will merge with and into Assertio, with Assertio surviving as a wholly owned subsidiary of Garda. The filing is an Amendment No. 1 to a Form 8-K dated April 8, 2026, correcting and replacing Item 1.01 and updating conformed signatures on certain exhibits.